Piroheptine was observed to prevent the reuptake of dopamine and is therefore a
DRI.[1][2]
Piroheptine comes from a family of drugs that includes
pridefine and
etifelmine.
References
^Saitoh T (February 1988). "Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl". Journal of the Neurological Sciences. 83 (2–3): 161–166.
doi:
10.1016/0022-510X(88)90065-2.
PMID3258627.
S2CID25230405.
^Ohashi T, Akita H, Tamura T, Noda K, Honda F (June 1972). "Effect of piroheptine, a new antiparkinson drug, on dopamine uptake into synaptosomes from corpus striatum of rat brain". Arzneimittel-Forschung. 22 (6): 966–972.
PMID5068358.
Piroheptine was observed to prevent the reuptake of dopamine and is therefore a
DRI.[1][2]
Piroheptine comes from a family of drugs that includes
pridefine and
etifelmine.
References
^Saitoh T (February 1988). "Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl". Journal of the Neurological Sciences. 83 (2–3): 161–166.
doi:
10.1016/0022-510X(88)90065-2.
PMID3258627.
S2CID25230405.
^Ohashi T, Akita H, Tamura T, Noda K, Honda F (June 1972). "Effect of piroheptine, a new antiparkinson drug, on dopamine uptake into synaptosomes from corpus striatum of rat brain". Arzneimittel-Forschung. 22 (6): 966–972.
PMID5068358.